Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Albiglutide

Stage Phase 3Stale

Sponsor GlaxoSmithKline

Route oral and injection

Sources

registry, as of 2017-08-17Stale

https://clinicaltrials.gov/study/NCT00537719

Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.. Overall status COMPLETED. Phases PHASE1. Lead sponsor GlaxoSmithKline. Enrollment 34. Conditions Diabetes Mellitus, Type 2. This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.

ClinicalTrials.gov NCT00537719 protocol and results modules

registry, as of 2019-07-12Stale

https://clinicaltrials.gov/study/NCT02750930

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects. Overall status TERMINATED. Phases PHASE4. Lead sponsor GlaxoSmithKline. Enrollment 8. Conditions Diabetes Mellitus, Type 2. Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US) Food and Drug Administration (FDA), the European Medic

ClinicalTrials.gov NCT02750930 protocol and results modules

registry, as of 2017-01-09Stale

https://clinicaltrials.gov/study/NCT00849017

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor GlaxoSmithKline. Enrollment 309. Conditions Diabetes Mellitus, Type 2. The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.

ClinicalTrials.gov NCT00849017 protocol and results modules

registry, as of 2018-04-05Stale

https://clinicaltrials.gov/study/NCT02496221

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects. Overall status COMPLETED. Phases PHASE4. Lead sponsor GlaxoSmithKline. Enrollment 20. Conditions Diabetes Mellitus, Type 2. Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus. The primary objective of this study is to assess if a single dose of albiglutide can affect cholecystokinin-induced gallbladder emptyin

ClinicalTrials.gov NCT02496221 protocol and results modules

registry, as of 2017-02-28Stale

https://clinicaltrials.gov/study/NCT01098539

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.. Overall status COMPLETED. Phases PHASE3. Lead sponsor GlaxoSmithKline. Enrollment 507. Conditions Diabetes Mellitus, Type 2. This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately cont

ClinicalTrials.gov NCT01098539 protocol and results modules

registry, as of 2026-08-13Stale

https://clinicaltrials.gov/study/NCT05220917

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study. Overall status ACTIVE_NOT_RECRUITING. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 781430. Conditions Cardiovascular Events; Type2 Diabetes; Renal Disease. To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 rec

ClinicalTrials.gov NCT05220917 protocol and results modules

Studies

Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.

Registry NCT00537719

Phase Phase 1

Status Completed

Enrollment 34

Start 2007-12-07

Primary completion 2008-04-04

Study completion 2008-04-04

GSK716155

Comparator placebo

Population Diabetes Mellitus, Type 2

placebo

Population Diabetes Mellitus, Type 2

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Registry NCT02750930

Phase Phase 4

Status Terminated

Enrollment 8

Start 2016-10-07

Primary completion 2017-03-21

Study completion 2017-03-21

Albiglutide arm

Regimen once weekly

Weeks 26

Population Diabetes Mellitus, Type 2

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

Registry NCT00849017

Phase Phase 3

Status Completed

Enrollment 309

albiglutide

Regimen weekly

Weeks 12

Comparator placebo

Population Diabetes Mellitus, Type 2

placebo

Regimen weekly

Weeks 12

Population Diabetes Mellitus, Type 2

albiglutide up-titration

Regimen weekly

Weeks 12

Comparator placebo

Population Diabetes Mellitus, Type 2

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

Registry NCT02496221

Phase Phase 4

Status Completed

Enrollment 20

Start 2015-06-11

Primary completion 2015-10-13

Study completion 2015-10-13

Albiglutide / Placebo or Placebo / Albiglutide

Population Diabetes Mellitus, Type 2

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

Registry NCT01098539

Phase Phase 3

Status Completed

Enrollment 507

albiglutide

Regimen weekly

Population Diabetes Mellitus, Type 2

sitagliptin

Regimen weekly

Population Diabetes Mellitus, Type 2

CER-4-T2D

Registry NCT05220917

Status Active, not recruiting

Enrollment 781430

Start 2021-08-01

Primary completion 2026-05-31

Study completion 2027-09-30

Catalyst Primary completion. 2026-05-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

SGLT-2i (Comparison 1)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

DPP-4i (Comparison 1)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SGLT-2i (Comparison 2)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

GLP-1 RA (Comparison 2)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

GLP-1 RA (Comparison 3)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

DPP-4i (Comparison 3)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SGLT-2i (Comparison 4)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SU (Comparison 4)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

GLP-1 RA (Comparison 5)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SU (Comparison 5)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

DPP-4i (Comparison 6)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SU (Comparison 6)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SGLT2i (Comparison 7)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

GLP-1 RA (Comparison 7)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

DPP-4i (Comparison 7)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SU (Comparison 7)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

SGLT2i (Comparison 8)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

GLP-1 RA (Comparison 8)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease

DPP-4i (Comparison 8)

Population Cardiovascular Events; Type2 Diabetes; Renal Disease